Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Extoxnet (extension toxicology network), 4-aminopyridine
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Ustekinumab.
BTG Commences Phase IIa Study of Multiple Sclerosis
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.

Pages